Last reviewed · How we verify
SCT800
At a glance
| Generic name | SCT800 |
|---|---|
| Also known as | Immune tolerance induction only, Recombinant human coagulation factor VIII |
| Sponsor | Institute of Hematology & Blood Diseases Hospital, China |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Efficacy and Safety Evaluation Study of SCT800 in Previously Untreated Hemophilia A Patients. (PHASE3)
- ITI Using SCT800 Alone or Combining Daratumumab in Hemophilia A Adolescents and Adults With High Titer Inhibitor (PHASE4)
- Safety and Efficacy of Long-term Treatment With SCT800 in Previously Treated Hemophilia A Patients. (PHASE4)
- Evaluation of SCT800 in Prophylaxis Therapy on Previous Treated Patients With Severe Hemophilia A (PHASE3)
- Safety,Efficacy and Pharmacokinetics Evaluation of SCT800 in Previously Treated Paediatric Patients With Severe Haemophilia A. (PHASE3)
- Efficacy and Safety Study of SCT800 for On-demand Treatment With in Patients With Hemophilia A (PHASE3)
- Pharmacokinetic Study of SCT800 in Previously Treated Patients With Hemophilia A (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SCT800 CI brief — competitive landscape report
- SCT800 updates RSS · CI watch RSS
- Institute of Hematology & Blood Diseases Hospital, China portfolio CI